title: Are androgen receptor variants a substitute for the full-length receptor?
abstract: Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.
authors: Department of Urology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.
authors: Ji
authors: J
authors: Lu
authors: Department of Urology, Mayo Clinic, 200 First Street SW Rochester, MN 55905, USA.
authors: Travis
authors: T
authors: Van der Steen
authors: Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors: Donald J
authors: DJ
authors: Tindall
mesh_terms: D017398:Alternative Splicing; D000818:Animals; D018450:Disease Progression; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000378:metabolism; D020033:Protein Isoforms; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D020033:Protein Isoforms; D011944:Receptors, Androgen